| Name | Title | Contact Details |
|---|
TearLab Corporation develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation`s common shares trade on the NASDAQ Capital Market under the symbol `TEAR` and on the Toronto Stock Exchange under the symbol `TLB`. Dry Eye Disease (DED) is a chronic, progressive disease. Morgan Stanley’s Dry Eye Market Report (2003) estimates that 30 to 60 million Americans suffer from dry eye symptoms. Only 10 million are diagnosed with the disease. Millions more suffer worldwide. The TearLab™ Osmolarity System provides the first quantitative and objective diagnostic technology that allows doctors to effectively manage their dry eye patients. TearLab will allow practitioners to diagnosis DED patients early in the disease process allowing for early intervention. TearLab received the CE Mark for its TearLab Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 14 countries including the US.
Ortho Arch Laboratory Inc is a Kingsford Heights, IN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Crossroads Medical Associates is a Ellicott City, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Integrated Medical, Inc. is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Fortimedix Surgical is a fast growing medical device company with the ambition to inspire a new wave of technological advancement in the field of minimally invasive surgery. The company is headquartered in Nuth, The Netherlands, and has a US subsidiary in San Diego, CA. With a strong history as a global market leader in contract stent manufacturing, Fortimedix has been a trusted partner in the medical device industry for over 15 years. Building on our established position as a stent industry leader with state-of-the-art manufacturing capabilities, we have in-house control over the manufacturing of key components of our products, including the symphonX™ Surgical Platform. Thanks to our network within the medical device industry, we are able to work with various professional service providers for the supply of other platform components and services. This allows us to outsource cost by leveraging their expertise and infrastructure.